WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 202334
CAS#: 903499-49-0
Description: PRLX 93936 is a structural analogue of erastin with potential antineoplastic activity. Erastin analogue PRLX 93936 appears to inhibit mitochondrial outer membrane protein VDACs (voltage-dependent anion channels) 2 and 3, resulting in an oxidative, non-apoptotic cell death. Erastin analogue PRLX 93936 exhibits greater lethality in cell lines harboring mutations in the GTPase protein oncogenes HRAS and KRAS or the serine-threonine protein kinase oncogene BRAF than in non-tumorigenic cell lines. VDACs 2 and 3 are up-regulated in a wide variety of tumor cell lines.
MedKoo Cat#: 202334
Name: PRLX-93936
CAS#: 903499-49-0
Chemical Formula: C21H24N4O2
Exact Mass: 364.1899
Molecular Weight: 364.449
Elemental Analysis: C, 69.21; H, 6.64; N, 15.37; O, 8.78
Synonym: PRLX93936; PRLX 93936; PRLX-93936; analogue of erastin.
IUPAC/Chemical Name: 3-(2-ethoxyphenyl)-2-(piperazin-1-ylmethyl)quinazolin-4(3H)-one
InChi Key: OBWOSMGNXYUDFB-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H24N4O2/c1-2-27-19-10-6-5-9-18(19)25-20(15-24-13-11-22-12-14-24)23-17-8-4-3-7-16(17)21(25)26/h3-10,22H,2,11-15H2,1H3
SMILES Code: O=C1N(C2=CC=CC=C2OCC)C(CN3CCNCC3)=NC4=C1C=CC=C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not soluble in water.
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 364.449 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
PRLX 93936 is a product of extensive SAR work originating from a small molecule identified in a synthetic lethal screen against isogenic cell lines engineered to differentially express several genes including activated RasV12. Preclinical pharmacodynamic and toxicological studies, suggest that PRLX 93936 has great therapeutic potential and therefore, Prolexys initiated a Phase I clinical trial in August, 2007.
Note: Structure was from http://www.chemspider.com/Chemical-Structure.9734401.html (5/31/2016).
